About
Technology
Issues
FAQ
Links
Official Page
Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma.
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.